Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Oct 26;15(21):5146.
doi: 10.3390/cancers15215146.

The Real-Life Impact of mFOLFIRI-Based Chemotherapies on Elderly Patients-Should We Let It or Leave It?

Balázs Pécsi  1 , László Csaba Mangel  1
Affiliations

The Real-Life Impact of mFOLFIRI-Based Chemotherapies on Elderly Patients-Should We Let It or Leave It?

Balázs Pécsi et al. Cancers (Basel). .

Abstract

Aim: The oncologic treatment of elderly patients is going on with a lack of evidence due to their underrepresentation in clinical trials. Many data suggest that certain groups of elderly patients, like their younger counterparts, may benefit from the systemic treatment of their metastatic colorectal tumors (mCRC).

Method: We performed retrospective data analysis to investigate the clinical course of care and clinical outcomes of 515 patients who received first-line mFOLFIRI-based chemotherapy for mCRC between 1 January 2013 and 31 December 2018 at the Institute of Oncotherapy of the University of Pécs, focusing on a comparison of patients over and under 70 years of age, defined as the cut-off value.

Results: 28.7% of the 515 patients were 70 years old and older (median age 73.5 years). Compared to the data of the elderly patients, the younger group (median age 61.1 years) had a performance status that was significantly better (average ECOG 1.07 vs. 0.83, p < 0.0001), and significantly more patients received molecularly targeted agents (MTA) (21.6% vs. 51.8%, p < 0.0001); nevertheless, mPFS (241 vs. 285 days, p = 0.3960) and mOS (610 vs. 698 days, p = 0.6305) results did not differ significantly. Considering the 1y PFS OR and the 2ys OS OR values (0.94 [95%CI 0.63-1.41] and 0.72 [95%CI 0.47-1.09], respectively), only a non-significant trend was observed in OS favouring the younger population. Additional analysis of our data proved that the survival in patients over 70 years was positively affected by the addition of MTAs to the doublet chemotherapies, and the reasonable modifications/reductions in dose intensity and the addition of local interventions had similar positive effects as observed in the younger patients' group.

Conclusions: Age stratification of mCRC patients is not professionally justified. Patients over 70 years of age with good performance status and controlled co-morbidities benefit from systemic therapy, its modifications and local treatment to the same extent as younger patients. With the increasing incidence of age-related cancers due to the rising average lifespan, prospective randomised clinical trials are needed to determine the real value of systemic therapy in the elderly and the rational, objective methods of patient selection.

Keywords: cancer in the elderly; mFOLFIRI-based treatments; metastatic colorectal carcinoma.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Kaplan–Meier curve for comparison of progression-free survival and survival between age groups.
Figure 2
Figure 2
Effect of each treatment modification/addition on the odds ratio (OR) of PFS/OS.
See this image and copyright information in PMC

References

    1. Terret C., Zulian G.B., Naiem A., Albrand G. Multidisciplinary Approach to the Geriatric Oncology Patient. J. Clin. Oncol. 2007;25:1876–1881. doi: 10.1200/JCO.2006.10.3291. - DOI - PubMed
    1. Lu B., Li N., Luo C.-Y., Cai J.L., Lu M., Zhang Y.-H., Chen H.-D., Dai M. Colorectal cancer incidence and mortality: The current status, temporal trends and their attributable risk factors in 60 countries in 2000–2019. Chin. Med. J. 2021;134:1941–1951. doi: 10.1097/CM9.0000000000001619. - DOI - PMC - PubMed
    1. Vassilev Z., Guo H., Lin W., Xu J., Khan N. Age-related trends in the incidence of metastatic colorectal cancer over the last ten years: A retrospective analysis in commercially-insured population in the United States. J. Clin. Oncol. 2022;40((Suppl. S4)):46. doi: 10.1200/JCO.2022.40.4_suppl.046. - DOI
    1. Cardoso R., Guo F., Heisser T., Hackl M., Ihle P., De Schutter H., Van Damme N., Valerianova Z., Atanasov T., Májek O., et al. Colorectal cancer incidence, mortality and stage distribution in European countries in the colorectal screening era: An international population-based study. Lancet Oncol. 2021;22:1002–1013. doi: 10.1016/S1470-2045(21)00199-6. - DOI - PubMed
    1. Gini A., Jansen E.E.L., Zielonke N., Meester R.G.S., Senore C., Anttila A., Segnan N., Novak Mlakar D., de Koning H.J., Landstorp-Vogelaar I. Impact of colorectal cancer screening on cancer specific mortality in Europe: A systematic review. Eur. J. Cancer. 2020;127:224–235. doi: 10.1016/j.ejca.2019.12.014. - DOI - PubMed

LinkOut - more resources